A review of oral anti‐cancer agents with putative primary targets of VEGF and RET encompassing 66 clinical trials showed that approximately one‐third of patients required a dose reduction.27 In the real world, dose reductions may occur even more frequently compared to data in clinical trials since these patients are carefully selected and must meet stringent eligibility criteria. Here, RET is linked to cancer.